ClinicalTrials.gg
Not yet recruitingNCT07897721Updated Oct 28, 2026

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of PF-08165784 and Fulvestrant in Advanced Breast Cancer, Advanced or Metastatic Breast Cancer and Metastatic Breast Cancer (HR+/ HER2-), sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
268
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.

Planned enrollment
26th of 121
268 · median 75
Started
2026
with 1 other
Phase 1
37 of 182
2 open now
Primary completion
2030-03
later than 24 of 25 live
Registered
182nd of 182
by date

Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 26th largest by planned enrollment of the 121 interventional ones that give a count, is one of 2 that started in 2026, is one of 37 in phase 1, reaches primary completion later than 24 of the 25 other live ones, and was the 182nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.

This study is seeking participants with a specific type of breast cancer (BC) called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (CRC) (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.

All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

03

Conditions studied

  • Advanced Breast Cancer
  • Advanced or Metastatic Breast Cancer
  • Metastatic Breast Cancer (HR+/ HER2-)
  • Metastatic Colorectal Adenocarcinoma

Keywords

  • Carcinoma
  • Breast
  • Estrogen Receptor Positive Breast Cancer
  • HER2- Breast Cancer
  • Colon Cancer
  • PI3K mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Advanced or cancer of the breast or colon Part 1A, 1B, and 1C: HR+/- advanced or metastatic breast cancer with disease progression after at least 1 with an endocrine therapy and cyclin-dependent kinase (CDK)4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior antibody-drug conjugate (ADC) therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
  • Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutation
  • Archived tumor specimen or fresh tumor
  • (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Active or dermatologic conditions
  • Active within 3 years prior to enrollment
  • Advanced/, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
  • Major surgery or radiation therapy within 3 weeks prior to study entry
  • Prior irradiation to >25% of the bone marrow
  • Active or history of pneumonitis/interstitial lung disease requiring
  • Unmanageable ascites
  • Prior treatment with phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
  • Renal impairment
  • Hepatic dysfunction
  • Hematologic abnormalities
  • Uncontrolled diabetes
  • Cardiac abnormalities
  • Active or history of clinically significant gastrointestinal (GI) or inflammatory GI disease
  • Other unacceptable abnormalities or prohibited therapies as defined by protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation Cohort 1A

    PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug

    Drug: PF-08165784

  • Experimental
    Part 1 Dose Escalation Cohort 1B

    Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

    Drug: PF-08165784 · Drug: Fulvestrant

  • Experimental
    Part 1 Dose Escalation Cohort 1C

    Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

    Drug: PF-08165784 · Drug: Fulvestrant · Drug: Atirmociclib

  • Experimental
    Part 1 Dose Escalation Cohort 1D

    Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug

    Drug: PF-08165784 · Drug: Cetuximab

  • Experimental
    Part 2 Dose Optimization/Expansion Cohort 2A

    Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug

    Drug: PF-08165784 · Drug: Atirmociclib · Drug: Letrozole

Interventions

  • DrugPF-08165784

    Taken by mouth (PO)

  • Selective Estrogen Receptor Degrader (SERD)

    Also known as: Faslodex

  • Selective cyclin-dependent kinase 4 (CDK4) inhibitor

    Also known as: PF-07220060

  • Monoclonal antibody (EGFR inhibitor)

    Also known as: Erbitux

  • Nonsteroidal aromatase inhibitor

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)

    Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

    Time frame: Baseline up to 28 days

  2. Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  3. Part 1 (Dose Escalation): Number of participants with laboratory abnormalities

    Number of participants with laboratory test abnormalities.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  4. Part 2 (Dose Expansion): Objective Response Rate (ORR)

    ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Secondary outcomes

  1. Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  2. Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1

    DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  3. Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1

    CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  4. Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1

    DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  5. Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1

    PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  6. Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1

    TTR is defined as the time from start date of treatment to first documentation of CR or PR.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  7. Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)

    Evaluate the single and multiple dose pharmacokinetic (s) (PK) of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  8. Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)

    Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  9. Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)

    Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  10. Part 1: Effect of Food on Cmax

    Evaluate the effect of food on Cmax of PF-08165784 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  11. Part 1: Effect of Food on Tmax

    Evaluate the effect of food on Tmax of PF-08165784 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  12. Part 1: Effect of Food on AUClast

    Evaluate the effect of food on AUClast of PF-08165784 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  13. Part 2 (Dose Expansion): Number of participants with laboratory abnormalities

    Number of participants with laboratory test abnormalities.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  14. Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  15. Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784

    Evaluate the pre- and post-dose concentrations of PF-08165784

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  16. Part 2: Overall Survival (OS)

    OS is defined as time from from start date of treatment to the date of death due to any cause

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2030, 40 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 40 months is close to that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Oct 27, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Mar 22, 2030
CompletionEst.
Mar 21, 2032
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: conditions
  2. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897721
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Mar 22, 2030 (estimated)
Completion
Mar 21, 2032 (estimated)
Last update
Oct 28, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion